Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...
MONTREAL, April 15, 2026 /CNW/ - To help prepare students from all disciplines for the analytical skills increasingly sought after in the job market, the National Hockey League (NHL), SAP and HEC ...
The company who previously applied for water rights for the controversial Stratos Project data center in Box Elder County has ...
Taking a big-ticket project from concept to completion isn’t for the squeamish. The right location must be found: property with appropriate zoning and access to utilities. Sometimes, ready access to a ...
POPULAR courses on entry-level digital skills and lifelong learning have shown increasing demand, as Coursera Inc. released its annual study of learner trends based on data from over 2.1 million ...
Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results